IASLC TTLC 2024 | Delivery of tumor treatment fields (TTFields) in NSCLC

Ticiana Leal, MD, Winship Cancer Institute, Atlanta, GA, explains considerations for the delivery of tumor treatment fields (TTFields) therapy, according to the results of the Phase III LUNAR study (NCT02973789). The most common adverse side effect of TTFields was grade I and II dermatitis, which can be reduced by ensuring the skin is clean, shaven and bandages are rotated. Dermatitis treatment includes the use of topical steroids or antibiotics. Less common grade III skin toxicities may be removed, and TTFields treatment paused for up to 72 hours. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.